Key clinical point: Poor subjective sleep quality was associated with exacerbations in chronic obstructive pulmonary disease (COPD).
Major finding: After 18 months of follow-up, patients with at least one exacerbation of COPD had a median baseline Pittsburgh Sleep Quality Index (PSQI) score of 6.0 (interquartile range, 3.0 to 8.0), compared with a median of 5.0 (2.0 to 7.0) among patients without exacerbations (P = .01 for difference between groups).
Study details: Prospective observational study of 480 adults with COPD.
Disclosures: The CanCOLD study has received funding from the Canadian Respiratory Research Network, Astra Zeneca Canada, Boehringer Ingelheim Canada, GlaxoSmithKline Canada, Novartis, Merck Nycomed, Pfizer Canada, and Theratechnologies. Dr. Shorofsky had no disclosures. Several coinvestigators reported ties to GlaxoSmithKline, Novartis, Boehringer Ingelheim, Merck, Almirall, and Theratechnologies.
Shorofsky M et al. CHEST. 2019 May 28. doi: 10.1016/j.chest.2019.04.132.